Personalized early detection and prevention of breast cancer: ENVISION consensus statement

Nora Pashayan(University College London), Antonis C. Antoniou(University of Cambridge), Urška Ivanuš(Institute of Oncology Ljubljana), Laura J. Esserman(University of California, San Francisco), Douglas F. Easton(University of Cambridge), David French(Manchester Academic Health Science Centre), Gaby Sroczynski(Austrian Institute for Health Technology Assessment GmbH), Per Hall(Karolinska Institutet), Jack Cuzick(Queen Mary University of London), D. Gareth Evans(University of Manchester), Jacques Simard(Université Laval), Montserrat García‐Closas(National Cancer Institute), Rita K. Schmutzler(University Hospital Cologne), Odette Wegwarth(Max Planck Institute for Human Development), Paul D.P. Pharoah(University of Cambridge), Sowmiya Moorthie(PHG Foundation), Sandrine de Montgolfier(Institut de Recherche Interdisciplinaire en Sciences Sociales), Camille Baron(UniCancer Group), Zdenko Herceg(Centre international de recherche sur le cancer), Clare Turnbull(Institute of Cancer Research), Corinne Balleyguier(Institut Gustave Roussy), Paolo Giorgi Rossi(Azienda Sanitaria Unità Locale di Reggio Emilia), Jelle Wesseling(The Netherlands Cancer Institute), David Ritchie(University of Antwerp), Marc Tischkowitz(University of Cambridge), Mireille J. M. Broeders(Radboud University Nijmegen), Daniel Reisel(University College London), Andres Metspalu(University of Tartu), Thomas Callender(University College London), Harry J. de Koning(Erasmus MC), Peter Devilee(Leiden University), Suzette Delaloge(Institut Gustave Roussy), Marjanka K. Schmidt(The Netherlands Cancer Institute), Martin Widschwendter(Universität Innsbruck)
Nature Reviews Clinical Oncology
June 18, 2020
Cited by 435Open Access
Full Text

Abstract

The European Collaborative on Personalized Early Detection and Prevention of Breast Cancer (ENVISION) brings together several international research consortia working on different aspects of the personalized early detection and prevention of breast cancer. In a consensus conference held in 2019, the members of this network identified research areas requiring development to enable evidence-based personalized interventions that might improve the benefits and reduce the harms of existing breast cancer screening and prevention programmes. The priority areas identified were: 1) breast cancer subtype-specific risk assessment tools applicable to women of all ancestries; 2) intermediate surrogate markers of response to preventive measures; 3) novel non-surgical preventive measures to reduce the incidence of breast cancer of poor prognosis; and 4) hybrid effectiveness-implementation research combined with modelling studies to evaluate the long-term population outcomes of risk-based early detection strategies. The implementation of such programmes would require health-care systems to be open to learning and adapting, the engagement of a diverse range of stakeholders and tailoring to societal norms and values, while also addressing the ethical and legal issues. In this Consensus Statement, we discuss the current state of breast cancer risk prediction, risk-stratified prevention and early detection strategies, and their implementation. Throughout, we highlight priorities for advancing each of these areas.


Related Papers

No related papers found

Powered by citation graph analysis